Adaptive Biotechnologies Corp ADPT

About Adaptive Biotechnologies Corp (ADPT): stock profile, AI score and financials

Adaptive Biotechnologies Corp (ADPT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADPT at 41.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,038 of 2,925 stocks — the bottom half of the AI-ranked universe. ADPT scores in the top quartile across revenue growth (90.2), institutional flow (80.7). Areas of concern include balance sheet strength (15.9) and profitability (17.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Adaptive Biotechnologies Corp reports quarterly revenue of $71.6M, net income of $-39.8M, an operating margin of -22.0%. Top institutional holders of ADPT by reported 13-F value include VIKING GLOBAL INVESTORS, BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ADPT trades on the Nasdaq exchange and files with the SEC under CIK 1478320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Adaptive Biotechnologies Corp directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1478320 →